<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069288</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-007971-18</org_study_id>
    <secondary_id>CIC0203/082</secondary_id>
    <nct_id>NCT02069288</nct_id>
  </id_info>
  <brief_title>Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock</brief_title>
  <acronym>FLUDRO</acronym>
  <official_title>Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response, Gastric Mucosal Perfusion and Arterial Stiffness in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock (associated with relative adrenal insufficiency) is characterized by decreased
      arterial responsiveness to catecholamines. The association of hydrocortisone and
      fludrocortisone has demonstrated an improvement in survival in septic shock patients. If
      hydrocortisone has shown to increase vascular responsiveness, the role of fludrocortisone
      remains to be elucidated. The purpose of our study is to investigate the effect of a
      physiological dose of fludrocortisone alone on norepinephrine-mean arterial pressure
      dose-response relationship, gastric mucosal perfusion and arterial stiffness in patients with
      septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Problems of drugs supply by the manufacturer
  </why_stopped>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Norepinephrine-mean arterial pressure dose-response relationship</measure>
    <time_frame>1.5 h after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic arterial pressures, heart rate, cardiac output, systemic vascular resistances</measure>
    <time_frame>During 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic pressures, Augmentation Index (Aix).</measure>
    <time_frame>During 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness: Carotid-femoral Pulse Wave Velocity</measure>
    <time_frame>During 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humeral diameter and distensibility</measure>
    <time_frame>During 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric mucosal perfusion</measure>
    <time_frame>During 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma electrolytes, blood glucose, serum creatinine</measure>
    <time_frame>Each hour during 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin, aldosterone, norepinephrine, epinephrine, fludrocortisone, TNF alpha concentrations</measure>
    <time_frame>Each hour during 3 h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes excretion</measure>
    <time_frame>Each hour during 3 h after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>50 µg of fludrocortisone per os</description>
    <arm_group_label>1</arm_group_label>
    <other_name>9- alpha- fluorohydrocortisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet of placebo per os</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over than 18 years old

          -  Septic shock

          -  Haemodynamic stability (mean arterial pressure between 70 and 80 mmHg) for at least 1
             hour, with a norepinephrine dose less than 0,5 µg/kg/min

          -  Written informed consent

        Exclusion Criteria:

          -  Corticotherapy

          -  Known allergy to Fludrocortisone

          -  Esophageal or gastric disease

          -  Pregnant woman

          -  Inclusion in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno LAVIOLLE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BELLISSANT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Réanimation Chirurgicale - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fludrocortisone</keyword>
  <keyword>pharmacology</keyword>
  <keyword>septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

